Repligen has received $731,000 in research funding to support the ongoing development of new treatments for Friedreich’s ataxia from the Muscular Dystrophy Association (MDA).
The company said that the grant is expected to support the completion of preclinical GLP toxicology testing and GMP manufacture of a drug candidate for human clinical trials.
Support from the MDA not only provides important funding for Repligen’s research but it also provides access to a global network of scientists, physicians and patients. Reportedly, this is the second research grant that Repligen has received from the MDA to support its Friedreich’s ataxia program.
Walter Herlihy, president and CEO of Repligen, said: “We would like to thank the Muscular Dystrophy Association for their continued support of our Friedreich’s ataxia program. Funding from the MDA has allowed us to accelerate the development of a treatment that has the potential to be the first drug to modify the course of this very debilitating disease.”